GeodAIsics

Name: GeodAIsics
Brand: GeodAIsics

AI Native

Responsible AI for Healthcare

Est 2021

LinkedIn 2K|Website|FTEs 17|HQ Grenoble, Auvergne-Rhône-Alpes, FR

01Competitive Landscape

Narrative competitive analysis

Potential strengths for GeodAIsics: - Customization: press coverage suggests the vendor works on solutions tailored to health actors and that some partnerships involve transfer of developed assets; this may be attractive to strategic partners but may complicate maintenance and long-term support expectations. - Technical differentiation: the company describes a generative manifold-learning methodology that, if clinically validated, could address some challenges where labeled-data approaches are limited. Where alternatives often have advantages: - Regulatory footprint and enterprise readiness: some competitors publicly state CE-marked or FDA-cleared status for elements of their portfolios and maintain broader distribution partnerships. - Procurement confidence: more mature vendors often publish security whitepapers, integration guides, validation summaries, and provide broader reference lists. Adoption and market trend signals: - GeodAIsics appears active at European radiology events and has announced partnerships (examples include Dedalus; a partnership press release with HORIBA is cited in sources).

	GeodAIsics (BrainGML / BrainGML-AD)	icometrix (icobrain)	DeepTrace (TRACE4AD)
Starting Price	Not publicly listed	Not publicly listed (typically enterprise)	Not publicly listed
Suitable for	Organizations evaluating a generative manifold learning approach and personalized atlas concepts; organizations with EU/French relationships	Organizations seeking mature neuro quantification workflows; portfolio with public CE/FDA claims for specific offerings	Organizations evaluating an Alzheimer’s-focused AI product combining MRI and neuropsychological assessment
Key Strength	Technical approach based on GML and personalized atlases/digital model concepts; presence in regional events and partnerships	Established ecosystem partnerships; clearer public claims of CE/FDA for specific products	Alzheimer’s-focused product narrative; explicit software-as-medical-device framing
Key Weakness	Limited public pricing, limited third-party user reviews, and limited public documentation of enterprise security features	May be perceived as more standardized and less tailored; enterprise cost considerations	Less visibility than larger incumbents; validation and regulatory details require verification

01Competitive Landscape

Narrative competitive analysis

Potential strengths for GeodAIsics:

Customization: press coverage suggests the vendor works on solutions tailored to health actors and that some partnerships involve transfer of developed assets; this may be attractive to strategic partners but may complicate maintenance and long-term support expectations.
Technical differentiation: the company describes a generative manifold-learning methodology that, if clinically validated, could address some challenges where labeled-data approaches are limited.

Where alternatives often have advantages:

Regulatory footprint and enterprise readiness: some competitors publicly state CE-marked or FDA-cleared status for elements of their portfolios and maintain broader distribution partnerships.
Procurement confidence: more mature vendors often publish security whitepapers, integration guides, validation summaries, and provide broader reference lists.

Adoption and market trend signals:

GeodAIsics appears active at European radiology events and has announced partnerships (examples include Dedalus; a partnership press release with HORIBA is cited in sources).

	GeodAIsics (BrainGML / BrainGML-AD)	icometrix (icobrain)	DeepTrace (TRACE4AD)
Starting Price	Not publicly listed	Not publicly listed (typically enterprise)	Not publicly listed
Suitable for	Organizations evaluating a generative manifold learning approach and personalized atlas concepts; organizations with EU/French relationships	Organizations seeking mature neuro quantification workflows; portfolio with public CE/FDA claims for specific offerings	Organizations evaluating an Alzheimer’s-focused AI product combining MRI and neuropsychological assessment
Key Strength	Technical approach based on GML and personalized atlases/digital model concepts; presence in regional events and partnerships	Established ecosystem partnerships; clearer public claims of CE/FDA for specific products	Alzheimer’s-focused product narrative; explicit software-as-medical-device framing
Key Weakness	Limited public pricing, limited third-party user reviews, and limited public documentation of enterprise security features	May be perceived as more standardized and less tailored; enterprise cost considerations	Less visibility than larger incumbents; validation and regulatory details require verification

GeodAIsics

01Competitive Landscape

Narrative competitive analysis

02Market Map

01Competitive Landscape

Narrative competitive analysis

02Market Map